How much does Tivozanib cost?

Tivozanib was first approved by the U.S. FDA in March 2021 under the trade name Fotivda. It is an oral drug used to treat relapsed or refractory renal cell carcinoma. It contains Tivozanib monohydrate. Renal cell carcinoma (RCC) is a diverse group of malignancies with distinct histological features, molecular alterations, prognosis, and treatment responses.

Tivozanib is an oral VEGFR-1, VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor with extremely strong selectivity and potency. It has much lower affinity for other receptor tyrosine kinases than multi-target TKIs currently in clinical use. Due to its longer half-life in the blood circulation, it may be able to block VEGFRs more sustainably. Dose-related controlled hypertension is the most common drug-related side effect. Fatigue, hoarseness, and diarrhea are common side effects, regardless of dose. Because of its targeting specificity, tivozanib can be used with other drugs with low side effects. Simultaneous blocking of VEGF and mTOR signaling pathways provides the benefit of synergistic anti-tumor efficacy while also preventing treatment resistance. Therefore, overall the drug tivozanib is suitable for the treatment of patients with renal cell carcinoma and can be studied in multicenter clinical trials.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.